(Q37773040)

22 August 2017

1 reference

title

Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications (English)

1 reference

22 August 2017

Rupinder K Sodhi

1

1 reference

22 August 2017

Nirmal Singh

series ordinal

2

1 reference

22 August 2017

Amteshwar S Jaggi

series ordinal

3

1 reference

22 August 2017

publication date

12 July 2010

1 reference

22 August 2017

published in

Vascular Pharmacology

1 reference

22 August 2017

volume

53

1 reference

22 August 2017

issue

3-4

1 reference

22 August 2017

page(s)

77-87

1 reference

Role of poly(ADP-ribose) polymerase in rapid intracellular acidification induced by alkylating DNA damage

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Mitochondrial and nuclear cross talk in cell death: parthanatos

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Are insulin autoantibodies markers for insulin-dependent diabetes mellitus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Partial protection by poly(ADP-ribose) polymerase inhibitors from nitroxyl-induced cytotoxity in thymocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribosyl)ation in mammalian ageing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly ADP-ribose polymerase-1: an international molecule of mystery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Superoxide dismutase 1 knock-down induces senescence in human fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Interrelationship of changes in islet nicotine adeninedinucleotide, insulin secretion, and cell viability induced by interleukin-1 beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

PARP-1, a determinant of cell survival in response to DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Physiology and pathophysiology of poly(ADP-ribosyl)ation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose). The most elaborate metabolite of NAD+.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibitors of poly (ADP-ribose) synthetase protect rat proximal tubular cells against oxidant stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The protective effect of niacinamide on ischemia-reperfusion-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Cell biology. PARP-1--a perpetrator of apoptotic cell death?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The molecular inflammatory process in aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Long-term memory requires polyADP-ribosylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibition of HIV-1 IIIb replication in AA-2 and MT-2 cells in culture by two ligands of poly (ADP-ribose) polymerase: 6-amino-1,2-benzopyrone and 5-iodo-6-amino-1,2-benzopyrone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inflammation and endothelial dysfunction during aging: role of NF-kappaB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Preconditioning decreases ischemia/reperfusion-induced peroxynitrite formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

PARP inhibitors for cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Peroxynitrite-mediated DNA strand breakage activates poly (ADP-ribose) synthetase and causes cellular energy depletion in carrageenan-induced pleurisy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Parthanatos, a messenger of death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase: a molecular nick-sensor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Endogenous nitric oxide induced by interleukin-1 beta in rat islets of Langerhans and HIT-T15 cells causes significant DNA damage as measured by the 'comet' assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

An inhibitor of poly (ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

PARP inhibition reduces acute colonic inflammation in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Unexpected sensitivity of nonobese diabetic mice with a disrupted poly(ADP-Ribose) polymerase-1 gene to streptozotocin-induced and spontaneous diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

7 January 2021

The biology of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Protection against hypoxia-reoxygenation in the absence of poly (ADP-ribose) synthetase in isolated working hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase-1 is required for efficient HIV-1 integration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The molecular "Jekyll and Hyde" duality of PARP1 in cell death and cell survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The biochemistry of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly (ADP-ribose) polymerase-1 (PARP-1) genetic variants are protective against Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Protection against hydrogen peroxide induced injury in renal proximal tubule cell lines by inhibition of poly(ADP-ribose) synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

HIV-1 Tat protein is poly(ADP-ribosyl)ated in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

RNA interference directed against Poly(ADP-Ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose)polymerase-1 is required for integration of the human immunodeficiency virus type 1 genome near centromeric alphoid DNA in human and murine cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The role of poly(ADP-ribose) polymerase-1 in CNS disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

MNNG-induced cell death is controlled by interactions between PARP-1, poly(ADP-ribose) glycohydrolase, and XRCC1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribosyl)ation regulation of life and death in the nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

7 January 2021

PARP goes transcription

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Coenzymatic activity of randomly broken or intact double-stranded DNAs in auto and histone H1 trans-poly(ADP-ribosylation), catalyzed by poly(ADP-ribose) polymerase (PARP I).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Regulation of the enzymatic catalysis of poly(ADP-ribose) polymerase by dsDNA, polyamines, Mg2+, Ca2+, histones H1 and H3, and ATP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly (ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibition of poly(ADP-ribose) polymerase: reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The response of Parp knockout mice against DNA damaging agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and inflammation in aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

GPI 6150, a poly (ADP-ribose) polymerase inhibitor, exhibits an anti-inflammatory effect in rat models of inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerases: managing genome stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Toward a control theory analysis of aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribosyl)ation as a fail-safe, transcription-independent, suicide mechanism in acutely DNA-damaged cells: a hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Transcription factor Yin Yang 1 stimulates poly(ADP-ribosyl)ation and DNA repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribosylation) and genomic stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibition of poly(ADP-ribose) polymerase in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibition of poly(ADP-ribose) glycohydrolase by gallotannin selectively up-regulates expression of proinflammatory genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

PARP inhibition: PARP1 and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Streptozotocin-induced impairment of islet B-cell metabolism and its prevention by a hydroxyl radical scavenger and inhibitors of poly(ADP-ribose) synthetase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Molecular mechanisms of aging-associated inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Sirtuins: critical regulators at the crossroads between cancer and aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Centromere proteins Cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose): novel functions for an old molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Peroxynitrite production and activation of poly (adenosine diphosphate-ribose) synthetase in spinal cord injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The world according to PARP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Protective effects of caspase-9 and poly(ADP-ribose) polymerase inhibitors on ischemia-reperfusion-induced myocardial injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Oxidative stress, caloric restriction, and aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

PJ34, a poly-ADP-ribose polymerase inhibitor, modulates visceral mitochondrial activity and CD14 expression following thoracic aortic ischemia-reperfusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

PolyADP-ribose polymerase-1 (PARP-1) and the evolution of learning and memory.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Enhanced ADP-ribosylation and its diminution by lipoamide after ischemia-reperfusion in perfused rat heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Novel modulators of poly(ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(adenosine diphosphate-ribose) synthetase inhibitor 3-aminobenzamide alleviates cochlear dysfunction induced by transient ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Effects of deleting mitochondrial antioxidant genes on life span

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(adenosine diphosphate ribose) polymerase inhibition prevents necrosis induced by H2O2 but not apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase, reduces myocardial infarct size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Mechanisms of nitrosourea-induced beta-cell damage. Activation of poly (ADP-ribose) synthetase and cellular distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP-ribose) polymerase inhibitors suppress UV-induced human immunodeficiency virus type 1 gene expression at the posttranscriptional level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

PARP inhibitor development for systemic cancer targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Poly(ADP‐Ribose) Synthetase Activation: An Early Indicator of Neurotoxic DNA Damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.06.003

10.1016/J.VPH.2010.06.003

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference